At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 263 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Placebo, SCD-044_Low Dose (Dose 1), and 2 other interventions for Moderate to Severe Plaque Psoriasis. Completed, enrolled 263 participants across 50 sites in 5 countries.
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque Psoriasis
CountriesEl Salvador, Estonia, Georgia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartMar 2021
Primary CompletionNov 2024
Study CompletionAug 2025
TodayJul 2026
First PostedSep 28, 2020
Enrollment StartMar 25, 2021
Primary CompletionNov 20, 2024
Study CompletionAug 27, 2025
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.8 years ago
Interventions
Placebodrug
Placebo of SCD-044 product
SCD-044_Low Dose (Dose 1)drug
SCD-044 tablets in Low Dose (Dose 1)
SCD-044_Intermediate Dose (Dose 2)drug
SCD-044 tablets in Intermediate Dose (Dose 2)
SCD-044_High Dose (Dose 3)drug
SCD-044 in High Dose (Dose 3)